GenSight Biologics

Update in progress

SIGHT.PA (Paris)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

GenSight Biologics S.A. is a Paris-based clinical-stage biotechnology company developing therapies for neurodegenerative retinal diseases and CNS disorders. It uses gene therapy with mitochondrial targeting sequences and optogenetics. Lead candidates are LUMEVOQ, an AAV2 gene therapy in Phase III for Leber hereditary optic neuropathy due to ND4 mutations, and GS030, in Phase I/II for retinitis pigmentosa and dry AMD. Preclinical programs exist. It collaborates with multiple academic and industry partners. Incorporated 2012.

Company score

Sentiment: 0.24; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.41; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.14; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.15; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.20; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive